Review anchor
Tyrosine-protein kinase Blk
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
Evidence Snapshot
Tyrosine-protein kinase Blk
CHEMBL2250
SINGLE PROTEIN
Homo sapiens
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Tyrosine-protein kinase Blk as ChEMBL target CHEMBL2250, mapped to UniProt P51451. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL2250
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-14
www.ebi.ac.uk
UniProt accession
P51451
Tyrosine-protein kinase Blk
UniProt accession via ChEMBL component mapping
As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-14
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why Tyrosine-protein kinase Blk matters
Tyrosine-protein kinase Blk is reviewed as Tyrosine-protein kinase Blk (UniProt P51451); the current evidence base includes 33 approved drugs, 1930 compounds, and 463 assays, with lead potency reaching pChEMBL 10.0.
Protein context
Tyrosine-protein kinase Blk
Tyrosine-protein kinase Blk Sequence length is 505 aa.
Review this target as Tyrosine-protein kinase Blk, mapped to UniProt P51451. Sequence length is 505 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt P51451
Protein
Disease context
Disease signal
Disease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordActivity base
Portfolio and assay base
ChEMBL currently tracks 33 approved drugs, 1930 compounds, and 463 assays for this target. The dominant activity type is KI. CHEMBL1873475 is the current potency anchor at pChEMBL 10.0.
Use CHEMBL1873475 as the tractability anchor when discussing potency (pChEMBL 10.0).
Activity source · ChEMBL 36 via Core Engine
33 approved
pChEMBL 10.0
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why Tyrosine-protein kinase Blk matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt P51451, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
1930
Total Compounds
463
Total Assays
33
Approved Drugs
IC50: 330.0, KI: 668.0, EC50: 25.0, KD: 134.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL1873475
|
10.0 | IC50 | Approved |
|
|
No preferred name
CHEMBL3647967
|
9.7 | IC50 | — |
|
|
No preferred name
CHEMBL4211949
|
9.7 | IC50 | — |
|
|
No preferred name
CHEMBL5416410
|
9.7 | Kd | Approved |
|
|
No preferred name
CHEMBL5189379
|
9.3 | IC50 | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
QUIZARTINIB
CHEMBL576982
|
2023 |
|
|
BELUMOSUDIL
CHEMBL2005186
|
2021 |
|
|
FEDRATINIB
CHEMBL1287853
|
2019 |
|
|
ZANUBRUTINIB
CHEMBL3936761
|
2019 |
|
|
ENTRECTINIB
CHEMBL1983268
|
2019 |
|
|
MIDOSTAURIN
CHEMBL608533
|
2017 |
|
|
BRIGATINIB
CHEMBL3545311
|
2017 |
|
|
NERATINIB
CHEMBL180022
|
2017 |
|
|
ACALABRUTINIB
CHEMBL3707348
|
2017 |
|
|
NINTEDANIB
CHEMBL502835
|
2014 |
|
|
IBRUTINIB
CHEMBL1873475
|
2013 |
|
|
AFATINIB
CHEMBL1173655
|
2013 |
|
|
AFATINIB DIMALEATE
CHEMBL2105712
|
2013 |
|
|
BOSUTINIB
CHEMBL288441
|
2012 |
|
|
VANDETANIB
CHEMBL24828
|
2011 |
|
|
CRIZOTINIB
CHEMBL601719
|
2011 |
|
|
NILOTINIB
CHEMBL255863
|
2007 |
|
|
DASATINIB
CHEMBL5416410
|
2006 |
|
|
SUNITINIB
CHEMBL535
|
2006 |
|
|
SORAFENIB
CHEMBL1336
|
2005 |
|
|
ERLOTINIB
CHEMBL553
|
2004 |
|
|
GEFITINIB
CHEMBL939
|
2003 |
|
|
IMATINIB
CHEMBL941
|
2001 |
Source Header